Axsome Therapeutics vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Axsome Therapeutics Inc (AXSM)

Q3 202610 Aug – 25 Sep 2026

▲4

Axsome's Alzheimer's Launch Drives Record Prescriptions, Pipeline Advances

Record Auvelity Prescriptions on Alzheimer's Launch Auvelity prescriptions hit a record ~23,500 weekly, with new-to-brand scripts reaching 3,800 as the Alzheimer's agitation launch grows. Patients 65+ now make up 31% of new scripts, up from 19%, showing strong demand and supporting the $8 billion peak-sales outlook.
This is the core demand driver behind the stock's recent move and the biggest new commercial catalyst.
Pipeline Advances with AXS-12 PDUFA and Phase III Start AXS-12 for cataplexy got a May 1, 2027 PDUFA date, and Axsome dosed the first patient in a Phase III study of AXS-05 for smoking cessation. Management targets roughly one new drug filing per year through 2030, expanding the pipeline beyond current products.
Shows new growth opportunities beyond Auvelity, which supports the long-term investment case.
Strong Q2 Revenue and Path to Cash Flow Positive Q2 net product revenue rose 46% to $218 million, led by Auvelity and Sunosi. Management expects revenue to grow faster than expenses, with $320 million cash funding operations into cash flow positivity, reducing financing risk.
Financial strength and profitability path are key to sustaining investor confidence.
Analyst Backing and New Clinical Data B. Riley named Axsome a top biotech pick with a $300 price target ahead of Q3 earnings. New clinical data in depression and Alzheimer's agitation were presented, adding detail to the pipeline and supporting future regulatory interactions.
Analyst endorsement and data reinforce the growth narrative and can attract investors.

September 202610 Aug – 25 Sep 2026

▲4

Axsome's Alzheimer's Launch Drives Record Prescriptions, Pipeline Advances

Record Auvelity Prescriptions on Alzheimer's Launch Auvelity prescriptions hit a record ~23,500 weekly, with new-to-brand scripts reaching 3,800 as the Alzheimer's agitation launch grows. Patients 65+ now make up 31% of new scripts, up from 19%, showing strong demand and supporting the $8 billion peak-sales outlook.
This is the core demand driver behind the stock's recent move and the biggest new commercial catalyst.
Pipeline Advances with AXS-12 PDUFA and Phase III Start AXS-12 for cataplexy got a May 1, 2027 PDUFA date, and Axsome dosed the first patient in a Phase III study of AXS-05 for smoking cessation. Management targets roughly one new drug filing per year through 2030, expanding the pipeline beyond current products.
Shows new growth opportunities beyond Auvelity, which supports the long-term investment case.
Strong Q2 Revenue and Path to Cash Flow Positive Q2 net product revenue rose 46% to $218 million, led by Auvelity and Sunosi. Management expects revenue to grow faster than expenses, with $320 million cash funding operations into cash flow positivity, reducing financing risk.
Financial strength and profitability path are key to sustaining investor confidence.
Analyst Backing and New Clinical Data B. Riley named Axsome a top biotech pick with a $300 price target ahead of Q3 earnings. New clinical data in depression and Alzheimer's agitation were presented, adding detail to the pipeline and supporting future regulatory interactions.
Analyst endorsement and data reinforce the growth narrative and can attract investors.

Latest10 Aug – 25 Sep 2026

▲4

Axsome's Alzheimer's Launch Drives Record Prescriptions, Pipeline Advances

Record Auvelity Prescriptions on Alzheimer's Launch Auvelity prescriptions hit a record ~23,500 weekly, with new-to-brand scripts reaching 3,800 as the Alzheimer's agitation launch grows. Patients 65+ now make up 31% of new scripts, up from 19%, showing strong demand and supporting the $8 billion peak-sales outlook.
This is the core demand driver behind the stock's recent move and the biggest new commercial catalyst.
Pipeline Advances with AXS-12 PDUFA and Phase III Start AXS-12 for cataplexy got a May 1, 2027 PDUFA date, and Axsome dosed the first patient in a Phase III study of AXS-05 for smoking cessation. Management targets roughly one new drug filing per year through 2030, expanding the pipeline beyond current products.
Shows new growth opportunities beyond Auvelity, which supports the long-term investment case.
Strong Q2 Revenue and Path to Cash Flow Positive Q2 net product revenue rose 46% to $218 million, led by Auvelity and Sunosi. Management expects revenue to grow faster than expenses, with $320 million cash funding operations into cash flow positivity, reducing financing risk.
Financial strength and profitability path are key to sustaining investor confidence.
Analyst Backing and New Clinical Data B. Riley named Axsome a top biotech pick with a $300 price target ahead of Q3 earnings. New clinical data in depression and Alzheimer's agitation were presented, adding detail to the pipeline and supporting future regulatory interactions.
Analyst endorsement and data reinforce the growth narrative and can attract investors.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.